Adithya Cattamanchi, MD

Write a Review714-456-7720

Dr. Adithya Cattamanchi is a board-certified UCI Health pulmonologist who specializes in lung disorders and critical care medicine. His clinical focus is on the treatment and management of pulmonary infections as well as common lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Cattamanchi earned his medical degree at the UC San Francisco School of Medicine, where he completed a residency in internal medicine and a fellowship in pulmonary and critical care medicine. He also received a master's of science degree in clinical research at UC San Francisco. Before joining UCI Health and the UCI School of Medicine as chief of the Division of Pulmonary Diseases & Critical Care Medicine, he served as a pulmonologist and critical care medicine specialist at Zuckerberg San Francisco General Hospital and Trauma Center and as a professor with the UCSF School of Medicine and its Center for Tuberculosis. His research focus is on improving the diagnosis and treatment of people with tuberculosis (TB) to ensure that the disease is diagnosed early and treatment begun immediately for better outcomes and to prevent community transmission, particularly in regions around the world with high rates of TB. Working with basic scientists and engineers to identify novel biomarkers for TB screening and diagnosis, he has developed point-of-care platforms for biomarker detection and tested them in field studies to evaluate their impact on clinical decisions and patient outcomes. Cattamanchi is the author or co-author of nearly 200 articles in peer-reviewed medical journals. His published research includes the performance of TB diagnostics among people with TB and led studies funded by the National Institutes of Health (NIH) to increase molecular testing for TB in community health centers throughout Uganda and to improve molecular diagnosis of drug-resistant TB in the Philippines. He also is working on NIH-funded studies to reduce TB in high-density U.S. urban settings and to develop novel, noninvasive tests to diagnose TB in children.